Elevate your glaucoma management with HFA3

Eliminate the guess-work. Know where your patient is heading.

To claim your special offer please fill out the form below.

A ZEISS sales representative will get in contact with you shortly.

Unable to load form.

Make informed decisions with expert analysis of visual fields and disease progression, trusted by experts globally*

  • Gold Standard HFA perimetry with complete set of SITA strategies expands your co-management opportunities.
  • GPATM* is at your fingertips to flag fast progressors using SITA tests, old and new.
  • SITATM Faster. Threshold testing in two minutes or less.
  • SITA Faster 24-2C with added central test points captures important information in macula in one test.
  • Touch of a button Liquid Trial Lens and eye auto alignment shorten chair time, provide best test results.
  • HFA3 Review software. Modify reports or review results with the patient in your office on demand.
  • Windows 10 full connectivity, data security, and IT efficiency.

Find out what you have been missing, click here.

*GPA selected citations:

  • Ahrlich KG, De Moraes CG, Teng CC, et al. Visual field progression differences between normal-tension and exfoliative high-tension glaucoma. Invest Ophthalmol Vis Sci 2010; 51(3):1458–1463.
  • American Academy of Ophthalmology. Primary open-angle glaucoma - preferred practice patterns. San Francisco, CA: The American Academy of Ophthalmology; 2018.
  • Arnalich-Montiel F, Casas-Llera P, Muñoz-Negrete FJ, Rebolleda G. Performance of glaucoma progression analysis software in a glaucoma population. Graefes Arch Clin Exp Ophthalmol. 2009;247:391-397.
  • Bengtsson B, Patella VM, Heijl A. Prediction of glaucomatous visual field loss by extrapolation of linear trends. Arch Ophthalmol. 2009;127(12): 1610–5.
  • Canadian Ophthalmological Society Glaucoma Clinical Practice Guideline Expert Committee, Canadian Ophthalmological Society. Canadian Ophthalmological Society evidence-based clinical practice guidelines for the management of glaucoma in the adult eye. Can J Ophthalmol 2009; 44(suppl 1):S7–S93.
  • Chauhan BC, Garway-Heath DF, Goni FJ, et al. Practical recommendations for measuring rates of visual field change in glaucoma. Br J Ophthalmol 2008;92(4):569–573.
  • European Glaucoma Society Terminology and Guidelines for Glaucoma, 4th Edition - Chapter 3: Treatment principles and options Supported by the EGS Foundation: Part 1: Foreword; Introduction; Glossary; Chapter 3 Treatment principles and options. Br J Ophthalmol 2017;101(6):130–195.
  • Heijl A, Alm A, Bengtsson B, et al. The Glaucoma Guidelines of the Swedish Ophthalmological Society. Acta Ophthalmol Suppl (Oxf) 2012;251:1–40.
  • Heijl A, Bengtsson B, Chauhan B, Lieberman MF, Cunliffe I, Hyman L, Leske CM. A comparison of visual field progression criteria of 3 major glaucoma trials in Early Manifest Glaucoma Trial patients. Ophthalmology. 2008;115:1557-1565.
  • Heijl A, Leske CM, Bengtsson B, Hussein M for the EMGT Group. Measuring visual field progression in the Early Manifest Glaucoma Trial. Acta Ophthalmol. Scand. 2003,81:286-293.
  • Heijl A, Leske CM, Bengtsson B, Hyman L, Bengtsson B, Hussein M, for the Early Manifest Glaucoma Trial Group. Reduction of intraocular pressure and glaucoma progression - Results from the Early Manifest Glaucoma Trial. Arch Ophthalmol. 2002;120:1268-1279.
  • Leske MC, Heijl A, Hyman L, Bengtsson, B. Early Manifest Glaucoma Trial: design and baseline data. Ophthalmology. 1999; 106(11): 2144–53.
  • Nouri-Mahdavi K, Zarei R, Caprioli J. Influence of visual field testing frequency on detection of glaucoma progression with trend analyses. Arch Ophthalmol 2011;129(12):1521–1527.
  • Saunders LJ, Russell RA, Crabb DP. Measurement precision in a series of visual fields acquired by the standard and fast versions of the Swedish interactive thresholding algorithm: analysis of large-scale data from clinics. JAMA Ophthalmol 2015; 133(1):74–80.
  • Wu Z, Saunders LJ, Daga FB, Diniz-Filho A, Medeiros FA. Frequency of testing to detect visual field progression derived using a longitudinal cohort of glaucoma patients. Ophthalmology 2017;124(6):786–792.
  • Zhichao Wu, David P. Crabb, Balwantray C. Chauhan, Jonathan G. Crowston, Felipe A. Medeiros,
    Improving the Feasibility of Glaucoma Clinical Trials Using Trend-Based Visual Field Progression End Points, Ophthalmology Glaucoma, 2019; 2(2): 72-77.

*Offer is valid until August 31st, 2021. For U.S. customers only.